Search results for

The number of cattle in the U.S. has reached a low not seen since 1951. NPR's Scott Simon speaks with Zach and Kacie Scherler-Abney, ranchers in Oklahoma, about the challenges of the cattle industry.

The shutdown at the Department of Homeland Security is the latest example of bipartisan negotiations unraveling in the wake of a crisis that captures national attention.

When a loved one goes missing, relatives can feel guilty simply for eating, says Charlie Shunick, whose sister was kidnapped. Shunick now helps others navigate a nightmare "nobody is prepared for."

NPR's Steve Inskeep talks with John Bolton, a national security advisor in President Trump's first term, about the prospect and risks of pursuing regime change in Iran.

After two-and-a-half weeks of competition, the Winter Olympics are officially over. A look back at the best moments, breakout stars and biggest upsets of the Games.

NPR's Michel Martin speaks with Jennifer Bergman, who says she had to close her family's toy store business of 44 years in July 2025 due to President Trump's tariffs.

Tuesday marks four years since Russia launched its invasion of Ukraine. A look at the effects of the war and where the situation stands today.

More than a decade ago, Lisa Morehouse began her quest to tell a story of food and agriculture from each of the state’s 58 counties. She recently completed her epic journey and to honor her achievement, BAY MADE is sharing episodes from her series CALIFORNIA FOODWAYS.

Hundreds of Oakland teachers demonstrated near Lake Merritt yesterday to demand what they described as better pay and working conditions, as well as a budget that prioritizes students' development and outcomes.

In his State of the Union address on Tuesday night, President Trump once again touted new tax benefits for tipped workers, who like many Americans are feeling the pinch of higher prices.

One San Francisco school’s closure makes way for another’s expansion and resurfaces a decades-old tension.

The Food and Drug Administration aims to evaluate treatments for rare diseases based on plausible evidence that they would work — without requiring a clinical trial first.